While the inhibition of the RAF-MEK-MAPK pathways with specific inhibitors showed the limited clinical activity for KRAS-mutation bearing cancers including CRC as a single agent, numerous preclinical and clinical studies have demonstrated that combinatorial approaches targeting multiple downstream effectors of KRAS exerted a more promising antitumor effect [44,45,46,47,48]. Here, KRAS is linked to cancer.